The aim of this study was to evaluate the predictive value of the TSR on the histopathological response to neoadjuvant anthracycline and taxane‐based chemotherapy in patients with stage II/III HER2‐negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.